Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/11/2026

1. COO
2. ORCL
3. CHWY
4. AVAV
5. ADBE
6. SPY
7. META
8. NVDA
9. MSFT
10. ASO

Go back to Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
(NASDAQ: PTGX) Delayed: 145.16 +0.07 (0.05%)
Previous Close $145.09    52 Week High $24.52 
Open $143.29    52 Week Low $10.02 
Day High $146.51    P/E N/A 
Day Low $142.00    EPS $0.00 
Volume 543,130